William Blair Issues Negative Estimate for BDX Earnings

Becton, Dickinson and Company (NYSE:BDX - Free Report) - Investment analysts at William Blair dropped their Q3 2025 EPS estimates for shares of Becton, Dickinson and Company in a report released on Monday, July 14th. William Blair analyst A. Brackmann now forecasts that the medical instruments supplier will post earnings of $3.43 per share for the quarter, down from their prior estimate of $3.52. William Blair has a "Market Perform" rating on the stock. The consensus estimate for Becton, Dickinson and Company's current full-year earnings is $14.43 per share. William Blair also issued estimates for Becton, Dickinson and Company's FY2025 earnings at $14.20 EPS and FY2026 earnings at $14.75 EPS.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last released its quarterly earnings results on Thursday, May 1st. The medical instruments supplier reported $3.35 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $3.28 by $0.07. Becton, Dickinson and Company had a return on equity of 15.99% and a net margin of 7.28%. The business had revenue of $5.27 billion during the quarter, compared to the consensus estimate of $5.35 billion. During the same quarter in the previous year, the business earned $3.17 EPS. The company's quarterly revenue was up 4.5% on a year-over-year basis.

A number of other brokerages also recently weighed in on BDX. Barclays cut their target price on Becton, Dickinson and Company from $261.00 to $241.00 and set an "overweight" rating on the stock in a research note on Tuesday, June 3rd. Piper Sandler lowered Becton, Dickinson and Company from an "overweight" rating to a "neutral" rating and decreased their target price for the company from $260.00 to $185.00 in a research report on Friday, May 2nd. The Goldman Sachs Group downgraded shares of Becton, Dickinson and Company from a "buy" rating to a "neutral" rating and set a $192.00 price target on the stock. in a report on Friday, May 2nd. Morgan Stanley decreased their price objective on shares of Becton, Dickinson and Company from $280.00 to $196.00 and set an "overweight" rating for the company in a report on Tuesday, May 6th. Finally, Bank of America lowered shares of Becton, Dickinson and Company from a "buy" rating to a "neutral" rating and set a $190.00 price objective on the stock. in a research report on Thursday, May 1st. Eight equities research analysts have rated the stock with a hold rating and four have given a buy rating to the stock. According to data from MarketBeat, the company has an average rating of "Hold" and an average price target of $219.22.

Becton, Dickinson and Company Stock Down 0.2%

BDX stock traded down $0.30 during trading on Wednesday, reaching $180.60. The stock had a trading volume of 823,072 shares, compared to its average volume of 2,131,873. The company has a quick ratio of 0.64, a current ratio of 1.13 and a debt-to-equity ratio of 0.70. The company has a market capitalization of $51.76 billion, a price-to-earnings ratio of 34.49, a P/E/G ratio of 1.35 and a beta of 0.25. Becton, Dickinson and Company has a one year low of $163.33 and a one year high of $251.99. The company's 50 day moving average is $173.28 and its two-hundred day moving average is $204.71.

Becton, Dickinson and Company Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Monday, June 30th. Shareholders of record on Monday, June 9th were paid a $1.04 dividend. This represents a $4.16 annualized dividend and a yield of 2.30%. The ex-dividend date was Monday, June 9th. Becton, Dickinson and Company's dividend payout ratio is presently 79.39%.

Insider Buying and Selling

In other news, EVP David Shan sold 1,166 shares of the business's stock in a transaction dated Monday, June 2nd. The stock was sold at an average price of $171.19, for a total transaction of $199,607.54. Following the completion of the transaction, the executive vice president owned 4,575 shares of the company's stock, valued at approximately $783,194.25. The trade was a 20.31% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.36% of the stock is currently owned by insiders.

Institutional Trading of Becton, Dickinson and Company

Institutional investors have recently added to or reduced their stakes in the business. PFG Investments LLC lifted its position in Becton, Dickinson and Company by 32.7% in the second quarter. PFG Investments LLC now owns 2,601 shares of the medical instruments supplier's stock valued at $448,000 after purchasing an additional 641 shares during the last quarter. Chicago Capital LLC raised its holdings in Becton, Dickinson and Company by 23.7% in the 2nd quarter. Chicago Capital LLC now owns 1,227 shares of the medical instruments supplier's stock worth $211,000 after purchasing an additional 235 shares in the last quarter. DiNuzzo Private Wealth Inc. lifted its position in shares of Becton, Dickinson and Company by 68.1% in the 2nd quarter. DiNuzzo Private Wealth Inc. now owns 227 shares of the medical instruments supplier's stock worth $39,000 after purchasing an additional 92 shares during the period. Alliance Wealth Advisors LLC boosted its stake in shares of Becton, Dickinson and Company by 29.8% during the 2nd quarter. Alliance Wealth Advisors LLC now owns 2,408 shares of the medical instruments supplier's stock valued at $415,000 after purchasing an additional 553 shares in the last quarter. Finally, Oakworth Capital Inc. increased its position in shares of Becton, Dickinson and Company by 5.3% during the second quarter. Oakworth Capital Inc. now owns 1,498 shares of the medical instruments supplier's stock valued at $258,000 after buying an additional 75 shares during the period. 86.97% of the stock is currently owned by hedge funds and other institutional investors.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.